Targeted Therapy for Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Lung cancer is a complex disease with diverse molecular subtypes.
• Genomic profiling enables personalized medicine by identifying driver mutations.
• Targeted therapies have become central to precision oncology for non-small cell lung cancer (NSCLC).

Purpose of the Study:

• To provide an updated summary of targeted therapies for NSCLC.
• To contextualize recent research in NSCLC treatment.
• To guide practitioners and researchers on molecular alterations and targeted treatments.

Main Methods:

• Review of current literature on NSCLC molecular subtypes and targeted therapies.
• Analysis of standard of care treatments, recent approvals, and guidelines.
• Exploration of targeted treatments for specific genetic mutations (EGFR, ALK, ROS1, BRAF, RET, MET, HER2, KRAS).

Main Results:

• Identification of key molecular alterations driving NSCLC, including EGFR mutations and ALK/ROS1 fusions.
• Overview of established and emerging targeted therapies for these alterations.
• Discussion of rarer molecular targets like BRAF, RET, MET, HER2, and KRAS.

Conclusions:

• Understanding NSCLC molecular heterogeneity is crucial for selecting optimal therapies.
• Targeted therapies tailored to specific mutations represent the forefront of personalized lung cancer treatment.
• Continued research and genomic profiling are essential for advancing NSCLC care.